Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study

BACKGROUND: Previous studies of the second-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJAC) had reported that apatinib combined with chemotherapy improved the treatment outcomes. However, the benefits were sometimes limited due to the tolerance of con...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ying, Li, Huimin, Wu, Shusheng, Wang, Gang, Luo, Huiqin, Niu, Jiayu, Cao, Lulu, Hu, Xiaoxiu, Xu, Huijun, Jia, Wei, Sun, Yubei, Yao, Yiwei, Chen, Wenju, Ke, Lihong, Hu, Bing, Ji, Chushu, Sun, Yancai, Chen, Jian, Li, Mengge, He, Yifu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908117/
https://www.ncbi.nlm.nih.gov/pubmed/35280426
http://dx.doi.org/10.21037/atm-22-546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908117/
https://www.ncbi.nlm.nih.gov/pubmed/35280426
http://dx.doi.org/10.21037/atm-22-546

Ejemplares similares